New treatments for levodopa‐induced motor complications
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Levodopa (l‐dopa)‐induced motor complications, including motor fluctuations and dyskinesia, affect almost all patients with Parkinson's disease (PD) at some point during the disease course, with relevant implications in global health status. Various dopaminergic and nondopaminergic pharmacological approaches as well as more invasive strategies including devices and functional surgery are available to manage such complications. In spite of undisputable improvements during the last decades, many patients remain significantly disabled, and a fully satisfying management of l‐dopa–induced motor complications is still an important unmet need of PD therapy. This article reviews the recent trial results published from 2013 to April 2015 about pharmacological and nonpharmacological interventions to treat motor complications. Randomized controlled trials conducted in patients suffering from already established complications showed that new levodopa (l‐dopa) formulations such as intrajejunal l‐dopa–carbidopa infusion and bilayered extended‐release l‐dopa–carbidopa (IPX066) can improve motor fluctuations. Positive results were also obtained with a new monoamine oxidase B (MAO‐B) inhibitor (safinamide) and a catechol‐O‐methyltransferase COMT inhibitor (opicapone). Pilot data suggest that new formulations of dopamine agonists (inhaled apomorphine) are also of potential interest. The development of novel nondopaminergic adenosine A2A antagonists (istradefylline, preladenant, and tozadenant) to treat motor fluctuations showed conflicting results in phase 2 and phase 3 trials. For dyskinesia, trials with new amantadine extended‐release formulations confirmed the interest of the glutamatergic N‐methyl‐d‐aspartate (NMDA) antagonist approach. Positive pilot antidyskinetic effects were also recently reported using serotonin agents such as eltoprazine and glutamate mGluR5 modulators such as mavoglurant. However, the translation to clinical practice of such innovative concepts remains challenging, because subsequent phase 2 trials conducted to confirm the antidyskynetic effects of mavoglurant failed, leading to the interruption of the development of this compound for this indication. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716 · cited 1×
“0015).(12) Daily ontime without troublesome dyskinesia was also significantly increased.”
BackgroundHauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., Ondo, W., O'Connell, M., & Gupta, S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70025-5 · Cited by 210
Cited by
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
A clinical view on the development of technology‐based tools in managing Parkinson's disease
Maetzler, W., Klucken, J., & Horne, M. (2016) · Movement Disorders · doi:10.1002/mds.26673 · Cited by 162
The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Hong, C. T., Chan, L., & Bai, C.-H. (2020) · Nutrients · doi:10.3390/nu12061860 · Cited by 113
“Istradefylline, an FDA-approved adenosine A2A receptor antagonist currently used for treating PD, reduces off time and improves the motor symptoms of patients with PD albeit with complications including the exacerbation of dyskinesia [36].”
BackgroundChotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56
Metadata
- Authors
- Rascol, O., Perez‐Lloret, S., & Ferreira, J. J.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-08-21
- Volume
- 30
- Issue
- 11
- Pages
- 1451-1460
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1952010211
- Cited by
- 113
- References
- 3
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New treatments for levodopa‐induced motor complications. https://app.cochat.ai/papers/10.1002/mds.26362
- The paper
- Rascol, O., Perez‐Lloret, S., & Ferreira, J. J. (2015). New treatments for levodopa‐induced motor complications. Movement Disorders. https://doi.org/10.1002/mds.26362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.